Business
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
Interface facilitates ease of ordering within the dermatologic EMR platform FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nInterface facilitates ease of ordering within the dermatologic EMR platform\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced its agreement with ModMed to establish an interface with ModMed’s electronic health records system, EMA®. The interface is designed to enable dermatologic clinicians to order Castle’s DecisionDx® skin cancer tests from directly within a patient’s medical record in EMA.\n\n“At Castle, we are excited to facilitate the ordering of our skin cancer portfolio from directly within one of the most widely utilized dermatologic electronic health records systems, EMA,” said Toby Juvenal, chief commercial officer of Castle Biosciences. “We are committed to impacting patient care, and our diagnostic tests are designed to provide clinically-actionable information to clinicians and patients to inform disease management decisions. The EMA platform has been ranked #1 by dermatologists for the past eight years by Black Book. Our interface with this system is expected to streamline the ordering process and allow for delivery of Castle’s test results within the system.”\n\nCastle’s full suite of skin cancer tests will be available to order within EMA: DecisionDx®-Melanoma for cutaneous melanoma, DecisionDx®-SCC for cutaneous squamous cell carcinoma and the Company’s Comprehensive Diagnostic Offering for difficult-to-diagnose melanocytic lesions (comprised of myPath® Melanoma and DecisionDx® DiffDx™-Melanoma). Castle’s interface with EMA is expected to be complete by year-end 2021.\n\nAbout Castle Biosciences\n\nCastle Biosciences (Nasdaq: CSTL) is a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx® -CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (myPath® Melanoma and DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com.\n\nCastle ...